Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas

Abstract

Purpose: The purpose of this study was to address the question of “superiority of R-CHOP versus CHOP", with<br />addition of Rituximab to CHOP, regarding survival of patients suffering from DLBCL. Patients and methods: A cohort<br />retrospective design was used to conduct this study in a tertiary care hospital. A total of 100 patients (50 in each group)<br />were randomly selected. The primary and secondary end points were EFS, OS, PFS and DFS. Kaplan Meier survival<br />curve analysis (log rank, Breslow and Tarone ware tests) was employed to compare probability of survival for the two<br />groups (CHOP/ R-CHOP). Results: The mean primary and secondary clinical indicators were estimated for each group<br />(EFS, 1.7; 3.09 with a p value P=0.02), (OS, 0.60; 0.43 with a p value P=0.40), (PFS, 1.73; 3.57 with a p value P=0.002), (DFS, 0.02; 0.48 with a p value of P=0.00). Conclusion:The results for differences in clinical response were statistically significant in favor of the R-CHOP group.